Cargando…
Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study
INTRODUCTION: Intensive care unit (ICU) patients often suffer from subcutaneous oedema, due to administration of large fluid volumes and the underlying pathophysiological condition. It is unknown whether the presence of subcutaneous oedema impairs the absorption of dalteparin, a low molecular weight...
Autores principales: | Rommers, Mirjam K, Van Der Lely, Netty, Egberts, Toine CG, van den Bemt, Patricia MLA |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550968/ https://www.ncbi.nlm.nih.gov/pubmed/16790078 http://dx.doi.org/10.1186/cc4952 |
Ejemplares similares
-
Anti-Xa activity after subcutaneous administration of dalteparin in intensive care unit patients with and without subcutaneous oedema
por: Rommers, M, et al.
Publicado: (2005) -
A Case of Progressive Subcutaneous Œdema
por: Greig, D. M.
Publicado: (1916) -
Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients
por: van der Heijden, Charlotte D. C. C., et al.
Publicado: (2022) -
Willingness of patients to use unused medication returned to the pharmacy by another patient: a cross-sectional survey
por: Bekker, Charlotte, et al.
Publicado: (2019) -
Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study
por: Leendertse, Anne J, et al.
Publicado: (2011)